Parathyroid transplant for severe low calcium after thyroid removal
Part of Hormones & metabolism clinical trials.
This trial tests a parathyroid gland transplant for people with severe, long-term low calcium levels after thyroid removal. It aims to help those who still have symptoms despite high-dose calcium and vitamin D supplements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had your entire thyroid gland removed (total thyroidectomy) in the past.
- You have low calcium symptoms (like numbness or tingling) that require high doses of calcium (over 2000 mg daily) and vitamin D (over 2 mcg calcitriol daily), or you need IV calcium occasionally.
- Blood tests show you have low parathyroid hormone levels (hypoparathyroidism).
- You have been treated with medications for at least 1 year after thyroidectomy, but still have symptoms and abnormal blood tests.
- You are healthy enough for an organ transplant, with no active infections, no cancer that would be a problem, and no reasons you cannot take anti-rejection medicines or have surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a donated parathyroid gland can help people with low parathyroid hormone (hypoparathyroidism) control their calcium levels and reduce symptoms. Participants will receive transplant and short-term immune-suppressing drugs.
This trial looks at whether removing overactive parathyroid glands (parathyroidectomy) can help people who still have high calcium or low phosphate levels more than 6 months after a kidney transplant. If you have stable kidney function and meet certain blood test results, you may be able to join.
This study aims to find ways to detect and prevent low parathyroid function after thyroid surgery. If you are having your whole thyroid removed, joining could help researchers learn how to improve recovery.
This trial compares two surgical approaches for severe secondary hyperparathyroidism caused by kidney disease: removing all parathyroid tissue alone versus removing it and moving some tissue back into the body. The study aims to see which approach works better and is safer for controlling the hormone problem.
This trial is for adults with hypoparathyroidism who are already taking a drug called palopegteriparatide (TransCon PTH) at a certain dose. It tests whether higher doses of this drug can better control calcium levels and reduce the need for other supplements.
This study tests whether a new injectable medicine called XH-02 can safely treat hypoparathyroidism—a condition where your body doesn't make enough parathyroid hormone, causing low calcium levels. If your calcium isn't well-controlled with current treatments (calcium and vitamin D supplements), this trial might help.
Hear when a new Hypoparathyroidism Postprocedural trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.